SG10201800243XA - SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID - Google Patents
SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACIDInfo
- Publication number
- SG10201800243XA SG10201800243XA SG10201800243XA SG10201800243XA SG10201800243XA SG 10201800243X A SG10201800243X A SG 10201800243XA SG 10201800243X A SG10201800243X A SG 10201800243XA SG 10201800243X A SG10201800243X A SG 10201800243XA SG 10201800243X A SG10201800243X A SG 10201800243XA
- Authority
- SG
- Singapore
- Prior art keywords
- self
- fatty acid
- emulsifying composition
- emulsifying
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013149662 | 2013-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201800243XA true SG10201800243XA (en) | 2018-02-27 |
Family
ID=52346290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600337PA SG11201600337PA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
| SG10201800243XA SG10201800243XA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600337PA SG11201600337PA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160158184A1 (en) |
| EP (2) | EP3023099B1 (en) |
| JP (4) | JPWO2015008848A1 (en) |
| KR (1) | KR102275447B1 (en) |
| CN (4) | CN111939125A (en) |
| CA (1) | CA2918330C (en) |
| ES (1) | ES2841344T3 (en) |
| HK (1) | HK1222551A1 (en) |
| MY (1) | MY187003A (en) |
| PH (1) | PH12016500100A1 (en) |
| SG (2) | SG11201600337PA (en) |
| WO (1) | WO2015008848A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
| NZ789295A (en) | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN114053258A (en) | 2009-06-15 | 2022-02-18 | 阿马里纳药物爱尔兰有限公司 | Compositions and methods for lowering triglycerides without increasing LDL-C levels in subjects on concomitant statin therapy |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| JP2015522029A (en) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | Methods to reduce the risk of cardiovascular events in patients on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| KR102343494B1 (en) * | 2015-01-21 | 2021-12-24 | 모치다 세이야쿠 가부시키가이샤 | Self-emulsifying composition of ω3 fatty acids |
| WO2016117621A1 (en) * | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | Ω-3 fatty acid self-emulsifying composition |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018054265A1 (en) * | 2016-09-20 | 2018-03-29 | 张碧婷 | Hydrophilic lipid composition packaging composition, preparation and blending method for same, and applications thereof |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CN112218630A (en) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | Method of reducing the risk of a cardiovascular event in a subject |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN116407543A (en) * | 2021-12-29 | 2023-07-11 | 中国科学院上海药物研究所 | EPA-EE nano lipid composition, preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG155189A1 (en) | 2004-08-06 | 2009-09-30 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
| JP4629768B2 (en) * | 2008-12-03 | 2011-02-09 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Parallelization processing method, system, and program |
| EP2405902B1 (en) | 2009-03-09 | 2021-07-21 | Basf As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
| WO2010134614A1 (en) * | 2009-05-22 | 2010-11-25 | 持田製薬株式会社 | SELF-EMULSIFYING COMPOSITION OF ω3 FATTY ACID |
| JP5421674B2 (en) | 2009-07-01 | 2014-02-19 | 株式会社ファンケル | Emulsified composition for soft capsule and soft capsule |
| ES2661812T3 (en) * | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Compositions |
| JP5820256B2 (en) | 2011-02-10 | 2015-11-24 | 株式会社ファンケル | Self-emulsifying formulation |
-
2014
- 2014-07-17 EP EP14826603.4A patent/EP3023099B1/en active Active
- 2014-07-17 MY MYPI2016700151A patent/MY187003A/en unknown
- 2014-07-17 CA CA2918330A patent/CA2918330C/en active Active
- 2014-07-17 SG SG11201600337PA patent/SG11201600337PA/en unknown
- 2014-07-17 CN CN202010690422.1A patent/CN111939125A/en active Pending
- 2014-07-17 CN CN201480040469.6A patent/CN105530927A/en active Pending
- 2014-07-17 CN CN201911271882.4A patent/CN110840874A/en active Pending
- 2014-07-17 SG SG10201800243XA patent/SG10201800243XA/en unknown
- 2014-07-17 CN CN202010690704.1A patent/CN111888343A/en active Pending
- 2014-07-17 JP JP2015527342A patent/JPWO2015008848A1/en active Pending
- 2014-07-17 KR KR1020167001712A patent/KR102275447B1/en active IP Right Grant
- 2014-07-17 ES ES14826603T patent/ES2841344T3/en active Active
- 2014-07-17 EP EP20190189.9A patent/EP3763364A1/en active Pending
- 2014-07-17 WO PCT/JP2014/069114 patent/WO2015008848A1/en active Application Filing
- 2014-07-17 US US14/905,652 patent/US20160158184A1/en not_active Abandoned
-
2016
- 2016-01-15 PH PH12016500100A patent/PH12016500100A1/en unknown
- 2016-09-09 HK HK16110704.8A patent/HK1222551A1/en unknown
-
2019
- 2019-08-08 JP JP2019146152A patent/JP2020011958A/en active Pending
-
2021
- 2021-01-06 US US17/142,558 patent/US20210128510A1/en active Pending
-
2022
- 2022-02-01 JP JP2022013981A patent/JP2022062147A/en active Pending
-
2023
- 2023-12-04 JP JP2023204610A patent/JP2024028839A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024028839A (en) | 2024-03-05 |
| WO2015008848A1 (en) | 2015-01-22 |
| KR102275447B1 (en) | 2021-07-08 |
| MY187003A (en) | 2021-08-26 |
| EP3023099B1 (en) | 2020-09-30 |
| KR20160032120A (en) | 2016-03-23 |
| JP2020011958A (en) | 2020-01-23 |
| CN111939125A (en) | 2020-11-17 |
| CA2918330C (en) | 2022-08-30 |
| EP3763364A1 (en) | 2021-01-13 |
| CN111888343A (en) | 2020-11-06 |
| EP3023099A1 (en) | 2016-05-25 |
| CN110840874A (en) | 2020-02-28 |
| CN105530927A (en) | 2016-04-27 |
| PH12016500100B1 (en) | 2016-04-18 |
| US20210128510A1 (en) | 2021-05-06 |
| PH12016500100A1 (en) | 2016-04-18 |
| US20160158184A1 (en) | 2016-06-09 |
| CA2918330A1 (en) | 2015-01-22 |
| EP3023099A4 (en) | 2017-01-04 |
| SG11201600337PA (en) | 2016-02-26 |
| HK1222551A1 (en) | 2017-07-07 |
| ES2841344T3 (en) | 2021-07-08 |
| JPWO2015008848A1 (en) | 2017-03-02 |
| JP2022062147A (en) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201600337PA (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID | |
| HK1243324A1 (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID | |
| EP3735963C0 (en) | Self-emulsifying composition of omega-3 fatty acid | |
| IL249821A0 (en) | Omega-3 fatty acid ester compositions | |
| IL269227B (en) | Solid forms of treprostinil | |
| EP2861227A4 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| HK1206248A1 (en) | Compositions of statins and omega-3 fatty acids -3 | |
| EP3248599A4 (en) | Omega-3 fatty acid self-emulsifying composition | |
| EP3056090A4 (en) | Oil/fat composition containing polyunsaturated fatty acid | |
| SI2984490T1 (en) | Methods of producing omega-hydroxylated fatty acid derivatives | |
| EP2961729A4 (en) | The preparation of biopolyol esters for lubricant application | |
| PL2997117T3 (en) | Use of an ester | |
| EP2827868A4 (en) | Pharmaaceutical compositions comprising fatty acid esters | |
| EP3069615A4 (en) | Fat containing polyunsaturated fatty acid | |
| PL2996484T3 (en) | Use of tall oil fatty acid | |
| IL279291A (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters | |
| PT2860211T (en) | Phosphoric acid ester compositions with reduced hygroscopy | |
| EP2849578A4 (en) | Use of saponified tall oil fatty acid | |
| EP2968246A4 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| EP2929041A4 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| IL245588A0 (en) | Solid compositions of triglycerides and uses thereof | |
| EP2845585A4 (en) | Trehalose fatty acid ester composition | |
| HRP20182110T1 (en) | Composition of tiacumicin compounds | |
| EP2964772A4 (en) | Production of omega-3 fatty acids from pythium species | |
| SG10202103821WA (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |